Autism and associated behavioral disorders: Pharmacotherapeutic intervention

J. T. Gilman, R. F. Tuchman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

OBJECTIVE: To review the literature on autism and pervasive developmental disorders (PDDs) as well as their respective pharmacotherapies. DATA SOURCES: An Index Medicus, MEDLINE, and bibliographic search of the literature pertaining to autism, PDDs, and respective treatments. STUDY SELECTION: Because of the paucity of literature on the treatment of autism and PDDs, the selection of reported data for this review included both controlled and uncontrolled studies, as well as case reports and any other information reported in the literature on the treatment of these disorders. DATA SYNTHESIS: Autism and PDDs are severe developmental disabilities defined by behavioral criteria. These disorders are lifelong in nature and present in varying severity of clinical manifestations. Behavioral manifestations of patients with autism include core deficits in social interaction, communication, and imaginative activities, with a restricted repertoire of activities and interests. The present understanding of the neurochemical basis of the disorder is limited. The role of pharmacotherapy in the management of autism and PDDs is to ameliorate behavioral symptoms that interfere with the patients ability to participate in educational, social, work, and family systems. Agents that have shown positive clinical effects in the treatment of children with autism and PDDs are reviewed in this article. CONCLUSIONS: Autism is a complex developmental disorder representing a heterogeneous group of individuals with similar symptomatologies and multiple biologic etiologies. Present pharmacotherapeutic intervention seeks to resolve behavioral symptoms. Treatment of autism and PDDs requires appropriate delineation of the behaviors and neurobiologic disorders associated with each patient. No single therapeutic agent, or combination thereof, is appropriate for the treatment of all children and adults with autism or PDDs.

Original languageEnglish
Pages (from-to)47-56
Number of pages10
JournalAnnals of Pharmacotherapy
Volume29
Issue number1
StatePublished - Jan 1 1995

Fingerprint

Autistic Disorder
Behavioral Symptoms
MEDLINE
Therapeutics
Drug Therapy
Developmental Disabilities
Aptitude
Interpersonal Relations
Social Work
Communication

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Autism and associated behavioral disorders : Pharmacotherapeutic intervention. / Gilman, J. T.; Tuchman, R. F.

In: Annals of Pharmacotherapy, Vol. 29, No. 1, 01.01.1995, p. 47-56.

Research output: Contribution to journalArticle

Gilman, J. T. ; Tuchman, R. F. / Autism and associated behavioral disorders : Pharmacotherapeutic intervention. In: Annals of Pharmacotherapy. 1995 ; Vol. 29, No. 1. pp. 47-56.
@article{eb8cb05ca38f4cf09c48e700d1e770a0,
title = "Autism and associated behavioral disorders: Pharmacotherapeutic intervention",
abstract = "OBJECTIVE: To review the literature on autism and pervasive developmental disorders (PDDs) as well as their respective pharmacotherapies. DATA SOURCES: An Index Medicus, MEDLINE, and bibliographic search of the literature pertaining to autism, PDDs, and respective treatments. STUDY SELECTION: Because of the paucity of literature on the treatment of autism and PDDs, the selection of reported data for this review included both controlled and uncontrolled studies, as well as case reports and any other information reported in the literature on the treatment of these disorders. DATA SYNTHESIS: Autism and PDDs are severe developmental disabilities defined by behavioral criteria. These disorders are lifelong in nature and present in varying severity of clinical manifestations. Behavioral manifestations of patients with autism include core deficits in social interaction, communication, and imaginative activities, with a restricted repertoire of activities and interests. The present understanding of the neurochemical basis of the disorder is limited. The role of pharmacotherapy in the management of autism and PDDs is to ameliorate behavioral symptoms that interfere with the patients ability to participate in educational, social, work, and family systems. Agents that have shown positive clinical effects in the treatment of children with autism and PDDs are reviewed in this article. CONCLUSIONS: Autism is a complex developmental disorder representing a heterogeneous group of individuals with similar symptomatologies and multiple biologic etiologies. Present pharmacotherapeutic intervention seeks to resolve behavioral symptoms. Treatment of autism and PDDs requires appropriate delineation of the behaviors and neurobiologic disorders associated with each patient. No single therapeutic agent, or combination thereof, is appropriate for the treatment of all children and adults with autism or PDDs.",
author = "Gilman, {J. T.} and Tuchman, {R. F.}",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "29",
pages = "47--56",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "1",

}

TY - JOUR

T1 - Autism and associated behavioral disorders

T2 - Pharmacotherapeutic intervention

AU - Gilman, J. T.

AU - Tuchman, R. F.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - OBJECTIVE: To review the literature on autism and pervasive developmental disorders (PDDs) as well as their respective pharmacotherapies. DATA SOURCES: An Index Medicus, MEDLINE, and bibliographic search of the literature pertaining to autism, PDDs, and respective treatments. STUDY SELECTION: Because of the paucity of literature on the treatment of autism and PDDs, the selection of reported data for this review included both controlled and uncontrolled studies, as well as case reports and any other information reported in the literature on the treatment of these disorders. DATA SYNTHESIS: Autism and PDDs are severe developmental disabilities defined by behavioral criteria. These disorders are lifelong in nature and present in varying severity of clinical manifestations. Behavioral manifestations of patients with autism include core deficits in social interaction, communication, and imaginative activities, with a restricted repertoire of activities and interests. The present understanding of the neurochemical basis of the disorder is limited. The role of pharmacotherapy in the management of autism and PDDs is to ameliorate behavioral symptoms that interfere with the patients ability to participate in educational, social, work, and family systems. Agents that have shown positive clinical effects in the treatment of children with autism and PDDs are reviewed in this article. CONCLUSIONS: Autism is a complex developmental disorder representing a heterogeneous group of individuals with similar symptomatologies and multiple biologic etiologies. Present pharmacotherapeutic intervention seeks to resolve behavioral symptoms. Treatment of autism and PDDs requires appropriate delineation of the behaviors and neurobiologic disorders associated with each patient. No single therapeutic agent, or combination thereof, is appropriate for the treatment of all children and adults with autism or PDDs.

AB - OBJECTIVE: To review the literature on autism and pervasive developmental disorders (PDDs) as well as their respective pharmacotherapies. DATA SOURCES: An Index Medicus, MEDLINE, and bibliographic search of the literature pertaining to autism, PDDs, and respective treatments. STUDY SELECTION: Because of the paucity of literature on the treatment of autism and PDDs, the selection of reported data for this review included both controlled and uncontrolled studies, as well as case reports and any other information reported in the literature on the treatment of these disorders. DATA SYNTHESIS: Autism and PDDs are severe developmental disabilities defined by behavioral criteria. These disorders are lifelong in nature and present in varying severity of clinical manifestations. Behavioral manifestations of patients with autism include core deficits in social interaction, communication, and imaginative activities, with a restricted repertoire of activities and interests. The present understanding of the neurochemical basis of the disorder is limited. The role of pharmacotherapy in the management of autism and PDDs is to ameliorate behavioral symptoms that interfere with the patients ability to participate in educational, social, work, and family systems. Agents that have shown positive clinical effects in the treatment of children with autism and PDDs are reviewed in this article. CONCLUSIONS: Autism is a complex developmental disorder representing a heterogeneous group of individuals with similar symptomatologies and multiple biologic etiologies. Present pharmacotherapeutic intervention seeks to resolve behavioral symptoms. Treatment of autism and PDDs requires appropriate delineation of the behaviors and neurobiologic disorders associated with each patient. No single therapeutic agent, or combination thereof, is appropriate for the treatment of all children and adults with autism or PDDs.

UR - http://www.scopus.com/inward/record.url?scp=0028896456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028896456&partnerID=8YFLogxK

M3 - Article

C2 - 7711345

AN - SCOPUS:0028896456

VL - 29

SP - 47

EP - 56

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 1

ER -